- Home
- LGND vs VERA Comparison
LGND vs VERA Comparison
Compare LGND & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGND
- VERA
- Stock Information
- Founded
- LGND 1987
- VERA 2016
- Country
- LGND United States
- VERA United States
- Employees
- LGND N/A
- VERA N/A
- Industry
- LGND Biotechnology: Pharmaceutical Preparations
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- LGND Health Care
- VERA Health Care
- Exchange
- LGND Nasdaq
- VERA Nasdaq
- Market Cap
- LGND 2.2B
- VERA 2.4B
- IPO Year
- LGND 1992
- VERA 2021
- Fundamental
- Price
- LGND $120.67
- VERA $28.58
- Analyst Decision
- LGND Strong Buy
- VERA Buy
- Analyst Count
- LGND 6
- VERA 8
- Target Price
- LGND $145.00
- VERA $66.38
- AVG Volume (30 Days)
- LGND 79.6K
- VERA 985.9K
- Earning Date
- LGND 02-27-2025
- VERA 03-19-2025
- Dividend Yield
- LGND N/A
- VERA N/A
- EPS Growth
- LGND 160.46
- VERA N/A
- EPS
- LGND 2.47
- VERA N/A
- Revenue
- LGND $152,422,000.00
- VERA N/A
- Revenue This Year
- LGND $26.86
- VERA N/A
- Revenue Next Year
- LGND $14.95
- VERA N/A
- P/E Ratio
- LGND $48.82
- VERA N/A
- Revenue Growth
- LGND N/A
- VERA N/A
- 52 Week Low
- LGND $67.72
- VERA $25.99
- 52 Week High
- LGND $129.90
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- LGND 59.36
- VERA 29.57
- Support Level
- LGND $110.42
- VERA $25.99
- Resistance Level
- LGND $119.26
- VERA $34.79
- Average True Range (ATR)
- LGND 3.82
- VERA 2.15
- MACD
- LGND 0.61
- VERA -0.56
- Stochastic Oscillator
- LGND 81.35
- VERA 20.05
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.